| Literature DB >> 29458363 |
Edward Tieru Dassah1,2, Yaw Adu-Sarkodie3, Philippe Mayaud4.
Abstract
BACKGROUND: Effective implementation of rapid point of care tests (POCTs) for antenatal syphilis screening especially in settings where antenatal care attendance is high, can significantly increase screening coverage and treatment uptake. The operational challenges of introducing rapid syphilis POCTs at scale needs to be investigated. This study explores healthcare providers' experiences and challenges in antenatal syphilis screening following the national rollout of rapid syphilis POCTs in Ghana.Entities:
Keywords: Antenatal syphilis screening; Ghana; Health care providers; Point of care tests (POCTs); Rollout
Mesh:
Year: 2018 PMID: 29458363 PMCID: PMC5819248 DOI: 10.1186/s12913-018-2935-y
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Regions and level of healthcare facilities selected and healthcare workers interviewed
| Level of facility and staff | Number of facilities and staff selected in each region | |||
|---|---|---|---|---|
| Ashanti | Central | Northern | Total | |
| Level of facility | ||||
| Teaching or Regional Hospitala | 0 | 1 | 1 | 2 |
| District or Main Hospital | 3 | 2 | 2 | 7 |
| Private Hospital or Health Centre | 2 | 2 | 2 | 6 |
| Total | 5 | 5 | 5 | 15 |
| Healthcare staff | ||||
| Regional STI Coordinatorb | 1 | 1 | 0 | 2 |
| Medical Superintendents/Medical Officers | 3 | 5 | 3 | 11 |
| Medical Assistants | 1 | 2 | 1 | 4 |
| Midwives | 6 | 7 | 5 | 18 |
| Laboratory Scientists | 4 | 3 | 3 | 10 |
| Pharmacists/Dispensing Technicians | 4 | 1 | 3 | 8 |
| Total | 19 | 19 | 15 | 53 |
STI, sexually transmitted infection
aThe teaching and regional hospitals in the Ashanti region were not selected because: Syphilis test results were not routinely documented in the antenatal care register at the teaching hospital, and antenatal care attendance in the regional hospital was much lower than that of the selected district hospital. bThe regional STI coordinator for the Northern Region was not available for interview during our visit to the region
Thematic framework, personnel interviewed and key findings of investigation of syphilis POC testing policy in Ghana
| Themes and sub-themes | Personnel interviewed | Key findings |
|---|---|---|
| 1. Uptake and successes | ||
| • Syphilis testing for pregnant women | Facility in-charges, midwives and laboratory technologists | Almost all facilities were performing syphilis tests for pregnant women either at the antenatal clinic or laboratory |
| • Successes | Facility in-charges, midwives, pharmacists and laboratory technologists | Decentralisation of syphilis testing |
| 2. Staff training and facility level preparedness for rollout of treponemal POCTs | ||
| • Awareness of policy on antenatal syphilis screening | Facility in-charges, medical officers and midwives | All respondents aware of the need to screen all pregnant women for syphilis |
| • Knowledge of consequences of untreated maternal syphilis | Facility in-charges, medical officers and midwives | Almost all staff knew of an adverse pregnancy outcome due to maternal syphilis |
| • Training and retraining in the use of treponemal POCTs | Facility in-charges, midwives, laboratory technologists and STI coordinator | Midwives trained in all facilities |
| • Antenatal syphilis screening, treatment and referral guidelines | Facility in-charges, midwives, lab technologists and STI coordinator | No guidelines for antenatal syphilis screening |
| 3. Staff experiences and challenges | ||
| • Maternal syphilis as a component of health education during pregnancy | Midwives | All but one facility discussed maternal syphilis during health education sessions for pregnant women |
| • Experience of performing HIV and syphilis tests together | Midwives | Easier and time saving for healthcare providers |
| • Challenges | All | Stockouts of syphilis test kits and benzathine penicillin |
ANC - Antenatal care; POCT – Point of care test; STI - Sexually transmitted infection
Availability of screening/treatment protocols and referral guidelines for antenatal and neonatal interventions
| Number of facilities | |||
|---|---|---|---|
| Management Protocol/Guideline | Available, displayed | Available, not displayed | None available |
| Screening and treatment guidelines/cards ( | |||
| Syphilis screening guidelinesa | 0 | 0 | 13 |
| HIV screening guidelines | 8 | 3 | 4 |
| Malaria IPT administration guidelines | 11 | 1 | 3 |
| Tetanus toxoid administration guidelines | 13 | 1 | 1 |
| STI partner notification cards (HIV & syphilis) | 0 | 0 | 15 |
| Syphilis treatment protocols/cards ( | |||
| Treatment protocol for seropositive mothers | 1 | 1 | 11 |
| Treatment protocol for babies of seropositive mothers | 1 | 0 | 12 |
| HIV treatment protocols and referral guidelines | |||
| Treatment protocol for seropositive mothers ( | 8 | 0 | 0 |
| Treatment protocol for babies of seropositive mothers ( | 7 | 1 | 0 |
| Referral guidelines for treatment of seropositive mothers ( | 0 | 0 | 7 |
| Referral guidelines for treatment of babies of seropositive mothers ( | 0 | 0 | 7 |
STI, sexually transmitted infection; a2 facilities that had not started screening pregnant women for syphilis were excluded; b7 facilities that were not offering antiretroviral treatment for HIV were excluded; c8 facilities that were offering antiretroviral treatment for HIV were excluded
Stock levels of test kits, lancets, drugs and needles and syringes for HIV and syphilis testing and treatment
| Consumables | Stock levels | ||
|---|---|---|---|
| Nil | < 1 month | ≥1 month | |
| Test kits and lancets | |||
| Syphilis test kits ( | 6 | 0 | 7 |
| Syphilis test kits-chase buffer ( | 6 | 1 | 6 |
| HIV test kits/diluent ( | 0 | 4 | 10 |
| Lancets ( | 1 | 0 | 14 |
| Drugs and needles and syringes | |||
| Injection Benzathine penicillin ( | 8 | 1 | 6 |
| Tablets Erythromycin ( | 7 | 0 | 8 |
| Syrup Nevirapine ( | 0 | 2 | 6 |
| Tablets Sulphadoxine pyrimethamine ( | 2 | 1 | 12 |
| Needles and syringes ( | 1 | 0 | 14 |
a2 facilities which had not started syphilis screening were excluded; b1 facility which had not started antenatal HIV screening was excluded; c7 facilities that were not offering antiretroviral therapy (nevirapine) to babies of HIV positive mothers and referred all babies to other facilities for treatment were excluded